Former President Joe Biden’s recent diagnosis of stage 4 metastatic prostate cancer, marked by a Gleason score of 9, has raised questions about how such an advanced and aggressive cancer could have gone undetected despite his access to premier medical care. But this also underscores significant limitations in current prostate cancer screening protocols, particularly for older men
Limitations of PSA Testing
The prostate-specific antigen (PSA) blood test is a common tool for detecting prostate cancer. However, its efficacy is limited. Approximately 15 percent of men with normal PSA levels may still have prostate cancer, and about 80 percent of those with elevated PSA levels do not have the disease. Notably, aggressive cancers like Biden’s may not produce significant PSA levels, leading to false negatives.
In Biden’s case, it’s unclear whether regular PSA screenings were conducted. His last public physical in February 2024 did not mention a PSA test, prompting speculation about potential oversights.
Age-Based Screening Guidelines
U.S. guidelines often advise against routine PSA screening for men over 70 due to concerns about overdiagnosis and overtreatment of slow-growing cancers. This approach may inadvertently lead to missed diagnoses of aggressive cancers in older men.
Experts argue for more personalized screening strategies that consider individual risk factors such as age, family history, and race. For instance, according to the Bass Cancer Center, Black men and those with a family history of prostate cancer are at higher risk and may benefit from continued screening beyond age 70.
Diagnostic Challenges and Emerging Technologies
Traditional diagnostic methods like digital rectal exams (DRE) and standard biopsies have limitations. DREs can miss tumors, especially if they are small or located in less accessible areas of the prostate. Standard biopsies may not detect all cancers, particularly aggressive ones.
Emerging technologies, such as MRI-guided biopsies and artificial intelligence (AI)-assisted Gleason grading, show promise in improving detection rates. MRI-guided biopsies have demonstrated higher accuracy in identifying significant prostate cancers, compared to traditional methods. AI assistance in Gleason grading has been shown to enhance diagnostic accuracy and consistency among pathologists.
The Need for Personalized Screening Approaches
Biden’s diagnosis highlights the necessity for personalized screening strategies that account for individual risk factors. A one-size-fits-all approach may not be sufficient, especially for those at higher risk of aggressive prostate cancer. Personalized screening could lead to earlier detection and improved outcomes for high-risk individuals.
Conclusion
The advanced stage of President Biden’s prostate cancer, despite regular medical evaluations, underscores the limitations of current screening protocols. This case advocates for a reevaluation of screening guidelines, emphasizing the need for personalized approaches that consider individual risk factors and the adoption of emerging diagnostic technologies to improve early detection of aggressive prostate cancers.
Using President Biden’s stage 4 prostate cancer diagnosis to claim a “cover-up” or to further allegations of mental decline is both irresponsible and harmful – not just to him, but to the broader public. Health disclosures for public figures are important, but weaponizing a medical diagnosis erodes trust in institutions and undermines compassion. Serious illnesses like cancer often evolve quietly, even under regular medical supervision, especially in older adults. Suggesting a conspiracy in the absence of evidence fosters cynicism, not accountability.
Moreover, conflating a physical diagnosis like prostate cancer with cognitive fitness reflects a fundamental misunderstanding of both conditions. It stigmatizes the elderly and those managing illness, reinforcing ageist and ableist narratives. If every health challenge becomes a political scandal, we risk discouraging transparency among future leaders and normalizing invasive speculation.
The broader consequence is cultural: we become less empathetic, more divided, and less able to engage in fact-based dialogue. Health, like leadership, requires honesty and strength – qualities we should demand, but also support. Turning Biden’s cancer into political ammunition doesn’t just damage him – it sets a precedent that threatens how we treat every public figure, and every person, battling serious illness.
EDITOR’S NOTE:
The opinions expressed in this article are solely those of the author and do not necessarily represent the views or opinions of MedLearn Media. We provide a platform for diverse perspectives, but the content and opinions expressed herein are the author’s own. MedLearn Media does not endorse or guarantee the accuracy of the information presented. Readers are encouraged to critically evaluate the content and conduct their own research. Any actions taken based on this article are at the reader’s own discretion.